1. Home
  2. SWBI vs LYEL Comparison

SWBI vs LYEL Comparison

Compare SWBI & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Smith & Wesson Brands Inc.

SWBI

Smith & Wesson Brands Inc.

HOLD

Current Price

$14.56

Market Cap

691.4M

Sector

Industrials

ML Signal

HOLD

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

HOLD

Current Price

$19.81

Market Cap

556.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SWBI
LYEL
Founded
1852
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Ordnance And Accessories
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
691.4M
556.1M
IPO Year
2000
2021

Fundamental Metrics

Financial Performance
Metric
SWBI
LYEL
Price
$14.56
$19.81
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
5
Target Price
$14.00
$30.60
AVG Volume (30 Days)
405.2K
60.9K
Earning Date
06-17-2026
05-13-2026
Dividend Yield
3.37%
N/A
EPS Growth
N/A
N/A
EPS
0.05
N/A
Revenue
$474,661,000.00
$36,000.00
Revenue This Year
$7.61
N/A
Revenue Next Year
$3.72
$8,712.13
P/E Ratio
$291.20
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.73
$0.40
52 Week High
$15.79
$45.00

Technical Indicators

Market Signals
Indicator
SWBI
LYEL
Relative Strength Index (RSI) 44.96 38.13
Support Level $13.80 $15.82
Resistance Level $15.24 $27.30
Average True Range (ATR) 0.41 1.43
MACD -0.12 -0.33
Stochastic Oscillator 18.00 5.12

Price Performance

Historical Comparison
SWBI
LYEL

About SWBI Smith & Wesson Brands Inc.

Smith & Wesson Brands Inc is a U.S.-based leader in firearm manufacturing. It operates under one reportable segment: Firearms, which includes firearms distribution and manufacturing services. The company manufactures handguns, long guns, sporting rifles, shooting gear, and suppressor products. The firm's brand portfolio consists of Smith and Wesson, M&P, Thompson/Center Arms, Performance Center, and Gemtech; which are used for defense, law enforcement, hunting, and sporting purposes. The company operates internationally, with the majority of income generated by the U.S. market from its handgun products.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: